Dr. Galsky on the Rationale of the CheckMate 274 Trial in Urothelial Carcinoma
In Partnership With:
Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.
Matthew Galsky, MD, professor of Medicine (Hematology and Medical Oncology), director of genitourinary medical oncology, Icahn School of Medicine, Mount Sinai; codirector of the Center of Excellence for Bladder Cancer, and associate director for Translational Research at The Tisch Cancer Institute, discusses the rationale of the phase 3 CheckMate 274 trial (NCT02632409) in urothelial cancer.
CheckMate 274 evaluated adjuvant nivolumab (Opdivo) vs placebo in patients with high-risk, muscle-invasive urothelial cancer. Long-term data showed nivolumab maintained a disease-free survival benefit over placebo.
Radical surgery remains a standard treatment for muscle-invasive urothelial cancer, which involves removing the bladder for bladder cancer, or removing the kidney and the ureter for cancer of the upper urinary tract, Galsky explains. Despite surgery, a large subset of patients will still develop metastatic recurrence, Galsky says.
CheckMate 274 explored the use of adjuvant nivolumab as a systemic treatment to potentially decrease the risk of recurrence, Galsky concludes.
